| WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
| CN103702967A (en) | 2011-03-14 | 2014-04-02 | 貝丝以色列女执事医疗中心 | Methods and compositions for treatment of proliferative disorders |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
| JP6449764B2 (en) | 2012-06-07 | 2019-01-09 | ベス イスラエル デアコネス メディカル センター インコーポレイテッド | Methods and compositions for inhibition of PIN1 |
| CA2903091C (en) | 2013-03-15 | 2022-09-06 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| EP3091996B1 (en)* | 2014-01-11 | 2024-04-10 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Compositions and methods for in vitro assays of fibrin activity |
| US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
| US9968579B2 (en) | 2014-07-17 | 2018-05-15 | Beth Isreal Deaconess Medical Center, Inc. | ATRA for modulating Pin1 activity and stability |
| WO2016145186A1 (en) | 2015-03-12 | 2016-09-15 | Beth Israel Deaconess Medical Center, Inc. | Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| EP3620471A4 (en)* | 2017-05-02 | 2021-01-06 | National Cancer Center Japan | PLASMINE-CLEAVABLE, ANTI-INSOLUBLE-FIBRIN-ANTIBODY-ACTIVE CONJUGATE |
| JP7708374B2 (en)* | 2020-03-31 | 2025-07-15 | 国立研究開発法人国立がん研究センター | Fibrin-binding antibody and pharmaceutical composition comprising said antibody |
| EP4262870A4 (en)* | 2020-12-16 | 2024-10-30 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | USE OF FIBRIN-TARGETED IMMUNOTHERAPY TO REDUCE CORONAVIRUS PATHOGENESIS |
| WO2022159776A1 (en)* | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
| JP2024525188A (en)* | 2021-06-18 | 2024-07-10 | セリーニ バイオ インコーポレイテッド | Antibodies that bind to human fibrin or fibrinogen gamma C domain and methods of use - Patents.com |
| US20240279357A1 (en)* | 2021-06-18 | 2024-08-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE |
| WO2024044583A1 (en)* | 2022-08-22 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Human anti-fibrin antibodies and uses thereof |
| WO2024191900A2 (en)* | 2023-03-10 | 2024-09-19 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods and compositions for cellular immunotherapy – fib4 |